Wakade - Adrenergic Pharmacology II Flashcards
Metabolic Degradation of NE and EPI:
By what enzymes?
MAO and COMT
MAO:
o Location:
o Action in Nerve Terminals:
MAO:
o Location: nerve terminals (mitochondrial outer membrane), brain, liver, intestinal mucosa and neuronal tissue
o Action in Nerve Terminals: metabolizes free NE to regulate transmitter content in cytosol
COMT:
Location
Location: effector cells (smooth muscle, cardiac muscle etc.) and liver (cytosol)
Note: NOT found in brain or neuronal cells
Metabolism of NE/EPI:
MAO first
COMT first
o MAO first (nerve terminal) followed by COMT (liver)
o COMT first (effector cell or liver) followed by MAO (liver)- primary pathway*
Two Types of Adrenergic Receptors:
Alpha
Beta
Alpha Adrenergic Receptors primarily produce:
Exceptions:
Alpha: produce primarily CONTRACTION or EXCITATION
Exceptions: inhibition of intestinal smooth muscle, presynaptic nerve terminals, platelets and brain.
Beta Adrenergic Receptors primarily produce:
Exceptions:
Beta: produce primarily RELAXATION or INHIBITION
Exceptions: stimulation of heart and kidney cells
Can cell have both alpha and beta R?
Final response depends on what?
Cell/organ may have both alpha and beta R: and they may be activated simultaneously
Final response: depends on two factors
- Dominance of a certain type of receptor
- Type of adrenergic agent use
Two subtypes of alpha adrenergic R
Alpha1: post-synaptic smooth muscles of blood vessels, salivary glands, pancreas, internal sex organs etc.
Alpha2: presynaptic SS nerve terminals, blood platelets, CNS
Potencies:
Phenylphrine (PE) > Methoxamine
Alpha1 Phenylphrine (PE) > Methoxamine
Potencies:
Clonidine > Alpha-Methyl-NE»_space; Oxymetazoline
Alpha2 Clonidine > Alpha-Methyl-NE»_space; Oxymetazoline
Potencies:
Naphazoline = EPI = NE
Alpha1=Alpha2 Naphazoline = EPI = NE
Mechanism of Signaling (Alpha1):
Agonist binds Alpha1 receptor (coupled to Gq protein)
Gq alpha subunit released and binds GTP
Gq alpha + GTP –> Activates phospholipase C
PIP2 –> DAG and IP3 (by PLC)
DAG activates PKC
IP3 causes release of stored Ca++ and increase in free Ca++ (activates protein kinases)
Mechanism of Signaling (Alpha2):
Agonist binds Alpha2 receptor (coupled to Gi protein)
GTP kicks off GDP and binds Gi alpha subunit
Gi alpha + GTP –> Inhibits adenylyl cyclase –> decrease in cAMP
Beta-Adrenergic Receptors:
Two Subtypes:
Locations:
Beta1: located in the heart, kidney and adipose cells
Beta2: located in the vascular and bronchial smooth muscles
Potency
Beta 1
ISO > EPI > NE»_space;> PE
Potency
Beta2
ISO > EPI»_space;> NE»_space;> PE
Mechanism of Signaling (beta adrenergic receptors)
Agonist binds Beta receptor (coupled to Gs protein)
GTP kicks off GDP and binds to Gs alpha subunit
Gs alpha + GTP –> Activates adenylyl cyclase (AC) –> Increase in cAMP
Increase in cAMP –> Activation of various proteins and enzymes
Dopamine Receptors:
Location of major effects
What type of drugs act on DA receptors?
Major Effects: in CNS
Antipsychotics and neuroleptic drugs act through DA receptors
Two subtypes of DA-Rs
D1 and D2
D1 Family:
Subtype: Effect: Location: Effects on smooth muscle cells of BVs What is particularly rich in D1 receptors?
D1 Family (D5 Subtype):
Effect: increases cAMP
Location: Mainly CNS (striatum, hypothalamus, hippocampus)
Also in smooth muscle cells of blood vessels (particularly in renal vasculature)
- Vasodilation
- Natriuresis (loss of Na+)
- Diuresis
Renal vasculature
D2 Family:
Subtype:
Effect:
Location: (3)
Stimulation effects: (3)
(D3,D4 Subtypes):
Inhibits cAMP, blocks Ca++ channels and opens K+ channels
Location:
o Sympathetic ganglia
o Sympathetic nerve terminals
o Abundant in CNS (pituitary gland, substantia nigra, frontal cortex, medulla, hypothalamus)
Stimulation Effects:
o Hypotension
o Bradycardia
o Vasodilation
Relative Dopamine Potencies:
Dopamine: D1 = D2»_space; beta»_space; alpha
Fenoldopam: D1»_space; D2
Production of CV Actions by 3 Mechanisms:
- Releasing NE from adrenergic neurons (indirectly acting sympathomimetic)
- Interacting with alpha and beta adrenergic receptors
- Interacting with specific DA receptors